Skip to content

Study of Oxycyte in Severe Closed Head Injury

An Open Label, Proof of Concept Study, to Evaluate the Safety and Biological Effects of Oxycyte™ Perfluorocarbon in Patients With A Severe Head Injury Requiring Intracranial Pressure Monitoring-OX-CL-II-002

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00174980
Enrollment
9
Registered
2005-09-15
Start date
2005-09-01
Completion date
2008-04-01
Last updated
2026-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Brain Injury

Keywords

Oxycyte, perfluorocarbon oxygen carrier, brain oxygen tension

Brief summary

Brain damage as a result of decreased oxygen to the brain is found in 80% of patients that die with severe head injuries. Laboratory studies in animals and clinical trials have shown that increasing oxygen in the brain results in better brain oxygen consumption, less cell death, and better functional outcome. This study will test the hypothesis that Oxycyte is an effective way to increase brain oxygen levels in severe head injury.

Detailed description

Decreased brain oxygen in severe brain injuries appears to be implicated in poor functional outcome and death. Animal and clinical studies have shown that increasing brain oxygen in such patients improves functional outcome, and Oxycyte has been shown to be an effective means of delivering oxygen to tissues, including the brain. This study is an eight patient proof of concept study to test the effects of oxygen delivery with Oxycyte in patients with a severe traumatic head injury with a Glasgow Coma Scale (GCS) score of 3 to 9. Subjects diagnosed with a severe head injury (GCS 3-9) who receive a brain oxygen monitor and microdialysis catheter, will undergo baseline monitoring for 4 hours. In the first 4 subjects the Fi02 on the ventilator will be increased to 50% for a 4 hour stabilization period and this will be followed by a single intravenous infusion of 3ml/kg of Oxycyte. The Fi02 will remain at 50% for 24 hours. In the second 4 subjects the Fi02 on the ventilator will be increased to 100% for a 4 hour stabilization period and this will be followed by a single intravenous infusion of 3ml/kg of Oxycyte. The Fi02 will remain at 100% for 24 hours. Subjects will be enrolled, treated, and then monitored by LICOX 02 monitor before and after infusion of PFC, and then for at least 48 hours following the discontinuation of Oxycyte.

Interventions

intravenous infusion

Sponsors

Tenax Therapeutics, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* severe closed head injury patients or GCS 3-9 patients who receive brain oxygen monitoring * ventriculostomy/ICP monitor * at least one reactive pupil * no known life threatening disease prior to trauma * age 18-70 years old * consent for microdialysis/brain 02 monitoring * legal family representative present that can give informed consent for perfluorocarbon administration

Exclusion criteria

* no motor response * both pupils fixed and dilated * no consent available * allergy to egg proteins * coagulopathy * major liver injury * major pulmonary injury

Design outcomes

Primary

MeasureTime frame
Brain Dialysate Concentration Data40 hours

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORM. R Bullock, M.D.

Virginia Commonwealth University

Baseline characteristics

Characteristic
Age, Continuous33.3 years
STANDARD_DEVIATION 16
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
1 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
8 Participants
Region of Enrollment
United States
9 Participants
Sex: Female, Male
Female
2 Participants
Sex: Female, Male
Male
7 Participants

Adverse events

Event typeEG000
affected / at risk
other
Total, other adverse events
9 / 9
serious
Total, serious adverse events
2 / 9

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026